Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder. Pharmacologic management follows a structured, evidence-based approach with the goal of slowing muscle deterioration and preserving walking ability for as long as possible.
The established first-line pharmacologic intervention for DMD centres on corticosteroid therapy. Specific agent selection depends on individual patient characteristics; the complete regimen — including which agent, how it is used, and the full management algorithm — is outlined in the structured protocol.
Corticosteroids, such as prednisone, deflazacort, and vamoralone, are commonly prescribed to people with DMD to slow the progression of muscle weakness and delay the loss of ambulation (walking ability).
View source ↗